Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Vedanta Q2 EPS $0.17, Sales $4.06B

Vedanta (NYSE:VEDL) reported quarterly earnings of $0.17 per share. The company reported $4.06 billion in sales this quarter.

byBenzinga Newsdesk

October 29, 2021

1 minute read

Vedanta (NYSE:VEDL) reported quarterly earnings of $0.17 per share. The company reported $4.06 billion in sales this quarter.

Morgan Stanley Maintains Underweight on Citigroup, Lowers Price Target to $44

By Benzinga Newsdesk

Today, 11:45 AM

Morgan Stanley analyst Betsy Graseck maintains Citigroup (NYSE:C) with a Underweight and lowers the price target from $46 to $44.

Loop Capital Initiates Coverage On CVS Health with Buy Rating, Announces Price Target of $120

By Benzinga Newsdesk

Today, 11:45 AM

Loop Capital analyst Joseph France initiates coverage on CVS Health (NYSE:CVS) with a Buy rating and announces Price Target of $120.

CVS

Limbach Holdings Q4 EPS $0.41 Beats $0.40 Estimate, Sales $126.81M Miss $128.57M Estimate

By Benzinga Newsdesk

Today, 11:45 AM

Limbach Holdings (NASDAQ:LMB) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.40 by 2.5 percent. This is a 720 percent increase over earnings of $0.05 per share from the

LMB

Guggenheim Upgrades Teladoc Health to Neutral

By Benzinga Newsdesk

Today, 11:45 AM

Guggenheim analyst Sandy Draper upgrades Teladoc Health (NYSE:TDOC) from Sell to Neutral.

TDOC

Vedanta Q2 EPS $0.17, Sales $4.06B

Related Posts

Morgan Stanley Maintains Underweight on Citigroup, Lowers Price Target to $44

Loop Capital Initiates Coverage On CVS Health with Buy Rating, Announces Price Target of $120

Limbach Holdings Q4 EPS $0.41 Beats $0.40 Estimate, Sales $126.81M Miss $128.57M Estimate

Guggenheim Upgrades Teladoc Health to Neutral